Maia Biotechnology (MAIA) plans to start enrollment of certain patients resistant to checkpoint inhibitors and chemotherapy in a phase 3 study of THIO-104 for non-small lung cancer in H2.
The trial will evaluate the efficacy of THIO-104 administered in sequence with a checkpoint inhibitor to improve the overall survival of patients whose cancer has continued to grow after two previous lines of systemic treatment, the company said Thursday in a statement.
The study will enroll up to 300 patients in Asia, Europe and the US to compare the treatment with chemotherapy in 1-to-1 randomization, the company said.
Price: 1.85, Change: +0.01, Percent Change: +0.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。